‘ The agency writes, ‘An in-depth exploration of how this approach could be implemented occurred during the thematic session of the 30th UNAIDS Program Coordinating Plank meeting in Geneva on 6 June’ and discusses the session at length . This content was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family members Foundation. Kaiser Health Information, an independent news service editorially, is an application of the Kaiser Family members Foundation, a nonpartisan health care policy research business unaffiliated with Kaiser Permanente.At the time of the interim evaluation of overall survival, 29 sufferers were still receiving olaparib after a period of at least 21 months, and 4 patients were still getting placebo. The secondary end factors of modification in tumor size, mixed response rate according to RECIST suggestions and CA-125 measurement , and disease-control rate are reported in the Supplementary Appendix. Safety Nearly all patients had one or more adverse events, most of which were grade 1 or 2 2 . Adverse occasions with an incidence that was at least 10 percent higher in the olaparib group than in the placebo group, had been nausea, exhaustion, vomiting, and anemia.